Press release

DSM reports 2020 results

Heerlen, NL, 16 Feb 2021 07:00 CET

Highlights1

  • Continuing operations results2
  • DSM reports solid full year results in a challenging COVID-19 environment, led by good results in Nutrition and with a strong recovery in Materials in Q4
  • Group sales +1% and Adjusted EBITDA -1% 
    • Nutrition: sales +6%, organic sales +6%, Adjusted EBITDA +7%
    • Materials: sales -13%, volumes -6%, Adjusted EBITDA -27%
  • Adjusted net profit down 5% to €711m 

Total Group:

  • Net profit of €508m
  • Adjusted Net Operating Free Cash Flow of €955m, up 19%
  • Proposed dividend stable at €2.40 per ordinary share
  • Full year outlook 2021: Adjusted EBITDA growth into double digits

Key figures and indicators – continuing operations2

in € million Full year 2020 Full year 2019 % Change Volume Price/mix FX Other
Sales 8,106 7,998 1% 3% -1% -3% 2%
Nutrition 6,365 6,028 6% 5% 1% -3% 3%
Materials 1,518 1,744 -13% -6% -6% -1% 0%
Adjusted EBITDA 1,534 1,551 -1%        
Nutrition 1,338 1,250 7%        
Materials 272 372 -27%        
Innovation 21 26          
Corporate -97 -97          
EBITDA 1,368 1,457          
Adjusted EBITDA margin 18.9% 19.4%          

1) Adjusted EBITDA is an Alternative Performance Measure (APM) that reflects continuing operations.
Organic sales growth is the total impact of volume and price/mix.
Adjusted Net Operating Free Cash Flow is the cash flow from operating activities, corrected for the cash flow of the APM adjustments, minus the cash flow of capital expenditures and drawing rights.
2) Results excluding business held for sale

Co-CEOs statement

Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: “When faced with the unprecedented challenges from the pandemic, we remained determined to keep delivering for our customers, something that would not have been possible without the passion, resourcefulness and commitment of our exceptional colleagues. This enabled us to record a good financial performance in our Nutrition business, while Materials was significantly impacted by COVID-19. In Q4, business conditions in Human Nutrition remained strong, primarily in dietary supplements, reinforcing the importance of ‘health through nutrition’, while Animal Nutrition growth resumed after the mid-year destocking. Materials saw a very strong demand recovery driven by the automotive sector.

We continued to make good progress on the execution of our long-term strategic plan, including three specialty nutrition acquisitions that enhance our offering to customers, the divestment of Resins & Functional Materials, and delivering against our purpose-led sustainability ambitions in people and planet. With our innovation-focused growth platforms, we are firmly on track to deliver strong sales and earnings growth in coming years.

Whilst global uncertainty remains, looking ahead, we have a positive outlook for DSM in 2021.”

Outlook 2021

DSM expects to deliver an Adjusted EBITDA increase in Nutrition at the upper end of its mid-term strategic ambition of high single digit growth. Together with continued recovery in Materials, DSM expects an Adjusted EBITDA growth rate for the Group moving into double digits, with a continued good Adjusted Net Operating Free Cash Flow.

COVID-19 impact

COVID-19 led to unprecedented global challenges. DSM took very early actions to ensure the health and safety of its employees and partners while keeping operations running to serve customers with its essential products. Overall COVID-19 had a slightly negative effect on Group sales as Materials saw a negative impact of around 10% on volumes in the year due to reduced global demand in Q2 and Q3. Nutrition saw an overall slightly positive sales impact from COVID-19 mainly due to very strong demand in Human Nutrition for immunity-boosting products. DSM will continue to respond swiftly to COVID-19 health and safety developments and support the societies in which it operates.

Strategy

At its Virtual Investor Event in November 2020, DSM reiterated its purpose-led, performance-driven growth strategy. Sustainability and innovation are key growth drivers of DSM’s long-term focused strategic plan, which are underpinned by ambitious targets across People, Planet and Profit. In markets related to Nutrition, Health and Sustainable Living, DSM is well-positioned to use its capabilities to create a positive impact and deliver value for all stakeholders.

In Nutrition, DSM sees significant headroom for business growth and innovation. The success of Nutrition’s unique business model combining ‘global products’ and ‘local solutions’ is evident in its track record of 6% organic sales growth and a 10% Adjusted EBITDA growth CAGR 2015-2020. Recent acquisitions such as CSK, Glycom and the Erber Group further strengthened DSM’s value proposition to customers. Going forwards, Nutrition will maintain strong growth by building on its ‘global products’ and ‘local solutions’ model. In addition DSM will add a third leg through driving precision and personalization, by building on big data, digital and bioscience capabilities.

In Materials, DSM has strong growth and earnings potential, and is well positioned in the strategic area of Sustainable Living. Following the announcement of the sale of the Resins & Functional Materials businesses to Covestro AG, Materials’ activities now consist of DSM Engineering Materials and DSM Protective Materials. The company will continue to develop these into a more resilient, higher-growth, and high-margin specialty business. Its offering addresses the increasing demand for materials that protect the health of both people and planet by adding further bio-based and circular solutions.

Overall, DSM aims to deliver mid-single digit % organic sales growth, an above 20% Adjusted EBITDA margin, and high-single digit % Adjusted EBITDA growth on a mid-term basis in both Nutrition and Materials, supported by its strong innovation pipeline.

Q1 & Q3 reporting change

Starting in 2021, DSM will change its reporting cycle, in line with the established practice of many of its consumer ingredients peers. From Q1 2021, DSM will provide a trading update for Q1 and Q3 reporting sales, organic growth, Adjusted EBITDA and Adjusted EBITDA margins. DSM will organize media and analyst calls during half year and full year.

Q4 Highlights

Continuing operations results:

  • DSM reports a good Q4 despite significant negative foreign exchange effects
  • Group sales +8% and Adjusted EBITDA +5%:
    • Nutrition: sales +10%, organic sales +9%, Adjusted EBITDA +10%
    • Materials: sales +2%, volumes +14%, Adjusted EBITDA -10%
  • Adjusted net profit up 2% to €167m

Total Group:

  • Net profit of €55m
  • Adjusted net operating free cash flow of €316m, +26% compared to Q4 2019

Key figures and indicators – continuing operations

in € million Q4 2020 Q4 2019 % Change Volume Price/mix FX Other
Sales 2,080 1,934 8% 9% -1% -6% 6%
Nutrition 1,594 1,455 10% 7% 2% -7% 8%
Materials 426 417 2% 14% -9% -3% 0%
Adjusted EBITDA 390 373 5%        
Nutrition 324 294 10%        
Materials 85 94 -10%        
Innovation 5 7          
Corporate -24 -22          
EBITDA 348 324          
Adjusted EBITDA margin 18.8% 19.3%          

Nutrition delivered a strong sales performance in Q4, despite a significant negative foreign exchange effect of -7% which almost entirely offset the contribution of recent acquisitions. Business conditions overall were good, in line with expectations as communicated with the Q3 results.

Materials saw a strong sales recovery in Q4 driven by strong demand for Engineering Materials in the automotive markets. Protective Materials saw a partial recovery in its personal protection activities.

The complete version of this press release with accompanying financial statements and the Presentation to Investors are below in PDF format.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420

Dave Huizing

Vice-President Investor Relations
+31 45 578 2864

This site uses cookies to optimize your user experience.

Read more